Announcement: IO360° to highlight strategies for revolutionary cancer treatment

Conference brings business and clinical development approaches as well as scientific updates to accelerate clinical trials and FDA approval in the growing space of cancer immunotherapies

 The 2nd Annual Immuno-Oncology 360° (IO360°), a conference offering perspectives on the intricacies of business deals and clinical trial strategies with scientific data to revolutionize the way cancer is treated, will take place on February 2-3, 2016, at the New York Academy of Medicine, New York, USA, and the journal Advances in Modern Oncology Research (AMOR) highly encourages its Editorial Board Members and scientific readers to attend.

 IO360° – hosted by the Conference Forum with support from Cancer Research Institute, Society of Immunotherapy for Cancer and The Association for Cancer Immunotherapy – is the only conference that combines business and clinical development strategies with scientific updates to prepare the market for accelerating immuno-oncology (IO) clinical trials.

 “Over the past five years, the FDA has approved four new immunotherapies for prostate cancer, melanoma, and lung cancer, and more are going to come in the next five years. These include drugs like checkpoint inhibitors, chimeric antigen receptor (CAR) T cell therapies, cancer vaccines, and immune modulators, and combinations will be a key component,” noted Cancer Research Institute (CRI) in its press release on the IO360° event.

 “With the growth of cancer immunotherapy drug development on the rise, the approaches for business are undergoing a rapid change to keep up. The Immuno-Oncology 360° Conference will bring together business and clinical development strategies, as well as scientific updates, to accelerate clinical trials and FDA approval in the growing space of cancer immunotherapies,” CRI stated.

“[Immunotheraphy] is the first essential step to unlocking the true potential of the immune system to be able to reliably eradicate tumors in a high proportion of patients.”

-James Gulley

 

 IO360° co-chair James Gulley, head of Immunotherapy Section and director of Medical Oncology Service in Office of the Clinical Director at the National Cancer Institute’s Center for Cancer Research, said, “The activity we are seeing with immunotherapy is offering hope to many cancer patients. I think it is the first essential step to unlocking the true potential of the immune system to be able to reliably eradicate tumors in a high proportion of patients.”

 Axel Hoos, lead advisor and also co-chair of the IO360° programme, added: “Immunotherapy has undergone a very rapid change in just the past six months, and biopharma needs the information that will be beneficial to them in both clinical trials and partnering.”

“Immunotherapy has undergone a very rapid change in just the past six months, and biopharma needs the information that will be beneficial to them in both clinical trials and partnering.”

-Axel Hoos

 

 Hoos, who is also a CRI Scientific Advisory Council member, co-chairman of CRI’s Cancer Immunotherapy Consortium, and vice president for oncology research and development at GlaxoSmithKline, said, “This conference will deal with all of the things that business needs to know—who has partnered with whom, how has imaging and biomarkers been utilized in clinical trials, what the different modalities in immunotherapy are, and what combinations are being applied.”

 University of Pennsylvania cancer immunology expert Carl June, a recipient for the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in cancer immunotherapy, is scheduled to keynote on CAR-T data for Hematologic Malignancies.

 In addition, the programme will also include a keynote talk from Jedd Wolchok, chief of Melanoma and Immunotherapeutics Service at New York’s Memorial Sloan Kettering Cancer Center, along with additional talks by many other key leaders in the IO world.

 The second edition of IO360° event will delve into key areas of business, clinical and scientific advancements including:

  • Business Aspects for IO
  • Differences of Modalities in Immunotherapy
  • Methodological Advances – Investigating Immunotherapies in the Clinic
  • Immunotherapy Practice Altering Clinical Advances
  • Hematologic Malignancies
  • Emerging Biomarkers
  • Randomized Phase II Combination Therapy Trials

 For more information on the event’s list of distinguished speakers and topics of their talks, please visit IO360° website at http://theconferenceforum.org/conferences/immuno-oncology-360/overview.

 Interested participants can register at https://theconferenceforum.org/events/io-360-february-2016. Hurry up and take advantage of a 15% discount offered to registrants via AMOR by using the promo code AMOR.